Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape-Part II
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
Contributors
-
Joint Head of Behavioural Science -
Account Manager -
-
Associate Consultant -
Joint Head of Behavioural Science -
President, USA -
Vice President, Business Development -
Senior Consultant -
-
Publications Executive -
Project Director -
-
Strategic Communications Director -
Associate Consultant -
Executive Chairman -
Consultant -
-
Senior Consultant -
Consultant -
Senior Consultant -
SVP -
Master Practitioner: Patient Insights -
Publications Assistant -
EVP, Oncology Practice Head -
EVP, Patient Solutions -
-
US CEO -
-
Associate Editorial Director
-
Sr. Research Analyst -
-
Principal -
Research Executive -
Account Director -
-
-
Head of MedErgy (CH-MedErgy) -
-
Managing Consultant -
Marketing and Communications Manager -
Project Manager -
Project Director -
Executive Vice President, Strategic Collaborations -
Associate Consultant
Cello Health Archive
- January 2021 (1)
- December 2020 (2)
- November 2020 (1)
- October 2020 (2)
- September 2020 (3)
- August 2020 (6)
- July 2020 (3)
- June 2020 (1)
- May 2020 (1)
- April 2020 (2)
- March 2020 (6)
- February 2020 (19)
- January 2020 (4)
- December 2019 (3)
- November 2019 (4)
- October 2019 (1)
- September 2019 (2)
- August 2019 (4)
- July 2019 (4)
- June 2019 (4)
- May 2019 (12)
- April 2019 (11)
- March 2019 (5)
- February 2019 (12)
- January 2019 (1)
- October 2018 (2)
- August 2018 (5)
- July 2018 (7)
- June 2018 (5)
- May 2018 (5)
- April 2018 (6)
- March 2018 (9)
- February 2018 (11)
- January 2018 (4)
- December 2017 (8)
- November 2017 (21)
- October 2017 (35)
- September 2017 (18)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- May 2017 (2)
- April 2017 (2)
- March 2017 (1)
- February 2017 (2)
- January 2017 (1)
- December 2016 (1)
- October 2016 (1)
Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape-Part 1
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
Old dogs and new tricks – drug repurposing for rare diseases
In the same week as rare disease day and a summit on CAR-TCR looking at the ‘value’ assessment for incredible new gene and cell therapies...
Rare Diseases, cell therapies and the value conundrum - food for thought
Considerations around ‘value’ assessment for gene and cell therapies in rare diseases was a theme addressed by several speakers, to close...
Kite (a Gilead company) release unpublished data demonstrating the key determinants influencing durable responses in large B cell lymphoma patients treated with YESCARTA CAR-T therapy
Dr. Adrian Bot (VP of Translational Medicine – Kite, a Gilead Company) provides an update on the factors determining durable responses...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net